In a research report released Thursday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a price target of $147, after hosting a meeting with a clinician who specializes in seizures earlier this week and following that with GWPH management meetings.
Schimmer wrote, “We had an opportunity this week to host a lunch with a leading seizure specialist in Boston and then host GWPH management for meetings with investors. This provided us a unique opportunity to learn about key aspects of the seizure market and then check in with the company to understand how they’re preparing for eventual commercialization of Epidiolex, assuming positive Phase 3 trials in 1H16. We remain as confident as ever in prospects for Epidiolex to demonstrate a meaningful benefit in its clinical trials and emerge as one of the most exciting new products for seizures that has been seen for some time. As well, we remain highly impressed with GWPH’s preparedness for the Epidiolex opportunity and the thoughtful approach it is taking toward commercializing this unique product.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joshua Schimmer has a total average return of -10.3% and a 25% success rate. Schimmer has a 7.6% average return when recommending GWPH, and is ranked #3740 out of 3773 analysts.
All the 3 analysts polled by TipRanks rate GWPH stock a Buy. With a return potential of 62.6%, the stock’s consensus target price stands at $141.